Retrospective study of second line therapy in metastatic clear cell renal cell carcinoma patients treated with first-line immunotherapy combinations
Latest Information Update: 01 Jul 2022
At a glance
- Drugs Avelumab (Primary) ; Axitinib (Primary) ; Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
Most Recent Events
- 01 Jul 2022 New trial record
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology